AX-2026-042844 · CJC-1295 with DAC · GGPeps lot GGPE-2510-T1661

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.20	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.80	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — hydrolysed maleimide (+18 Da)	1.20	% area	≤ 1.00	FAIL
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.34	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.73	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.74	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	5.54	EU/mg	≤ 5.0	FAIL
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.45	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	14.61	min	14.62 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.03	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	78,806	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	1.22	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 78,806, and skew follows the reported asymmetry factor of 1.03. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.20 % impurity against a 98.20 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	CJC-1295 with DAC — main peak	14.61	4,772,824	98.20	—
2	hydrolysed maleimide (+18 Da)	13.99	58,324	1.20	+18.011
3	mod-GRF (1-29) (−279 Da)	12.85	14,095	0.29	-279.235
4	deamidated (+1 Da)	14.35	10,207	0.21	+0.984
5	maleimide dimer	17.03	4,860	0.10	+3644.975
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.57	98.20	divergence +0.56 pp vs batch median
Total impurities (% area)	not stated	1.80
Largest single impurity (% area)	not stated	1.20
Water (%)	4.0	6.34
Counter-ion (%)	7.7	3.73
Peptide content (%w/w)	87.7	not determined
Endotoxin (EU/mg)	not stated	5.54
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 10 d) → assay. Submitter did not handle the vial.
Assay date: 03 Mar 2026
Submitted to the index: 16 Mar 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

lal_assay16 Mar 2026

5.54 EU/mg is above the index screening threshold of 5.0. Two things to keep separate: the index threshold is a screening figure, and a real limit is dose-dependent. The endotoxin dose-limit calculator does that arithmetic. What this record establishes is that the burden is measurable and high relative to the rest of the dataset.

one_directional16 Mar 2026

Endotoxin determined but the LAL method is not stated. Kinetic chromogenic and gel-clot give different results and different sensitivity. The value cannot be interpreted without knowing which.

Contributor #S-452316 Mar 2026

5.54 EU/mg is elevated relative to the index median and the record shows no depyrogenation step. If this material will be reconstituted in aqueous buffer for any downstream use, that endotoxin load is a risk.

prep_hplc_cut16 Mar 2026

5.54 EU/mg is at the sensitivity limit of Janoshik's LAL method. The true value is unspecified; treating this as a point estimate is overstating precision.

Section 7

Related records

Same batch — lot GGPE-2510-T1661 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042836	GGPE-2510-T1661	Janoshik	2026-Q1	98.01	5.90	—	Supplier-supplied	3	MARGINAL
AX-2026-042837	GGPE-2510-T1661	Janoshik	2026-Q1	98.06	5.71	93.9	Supplier-supplied	1	MARGINAL
AX-2026-042838	GGPE-2510-T1661	Medutest	2026-Q1	97.96	5.62	—	Supplier-supplied	3	FAIL
AX-2026-042839	GGPE-2510-T1661	VendorInvestigate	2026-Q1	97.14	5.81	—	Buyer-sourced	1	FAIL
AX-2026-042840	GGPE-2510-T1661	Nordanalyt	2026-Q1	98.45	6.19	—	Supplier-supplied	2	MARGINAL
AX-2026-042841	GGPE-2510-T1661	Janoshik	2026-Q1	97.78	6.34	—	Laboratory-retained	2	FAIL
AX-2026-042842	GGPE-2510-T1661	Medutest	2026-Q1	97.52	5.79	—	Supplier-supplied	2	MARGINAL
AX-2026-042843	GGPE-2510-T1661	Janoshik	2026-Q1	98.21	5.49	—	Supplier-supplied	3	FAIL
AX-2026-042845	GGPE-2510-T1661	VendorInvestigate	2026-Q1	96.88	6.28	—	Buyer-sourced	1	FAIL
AX-2026-042846	GGPE-2510-T1661	Medutest	2026-Q1	98.00	6.16	—	Supplier-supplied	3	FAIL
AX-2026-042847	GGPE-2510-T1661	Janoshik	2026-Q1	98.61	6.04	102.7	Supplier-supplied	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent CJC-1295 with DAC records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041727	QSC	QSC-2602-E9474	Janoshik	2026-Q3	98.88	6.62	105.3	Supplier-supplied	1	MARGINAL
AX-2026-041728	QSC	QSC-2602-E9474	VendorInvestigate	2026-Q3	98.42	7.04	—	Buyer-sourced	1	MARGINAL
AX-2026-041734	QSC	QSC-2602-E9474	Medutest	2026-Q3	99.43	7.17	105.5	Supplier-supplied	2	FAIL
AX-2026-043539	BCH	BCH-2607-H7307	Janoshik	2026-Q3	98.12	5.78	100.6	Supplier-supplied	1	MARGINAL
AX-2026-041730	QSC	QSC-2602-E9474	PeptideMeter	2026-Q3	98.79	6.93	95.4	Supplier-supplied	1	MARGINAL
AX-2026-041731	QSC	QSC-2602-E9474	VendorInvestigate	2026-Q3	99.07	7.18	99.6	Buyer-sourced	1	MARGINAL
AX-2026-041725	QSC	QSC-2602-E9474	Medutest	2026-Q3	99.06	7.04	107.3	Supplier-supplied	2	FAIL
AX-2026-043537	BCH	BCH-2607-H7307	Janoshik	2026-Q3	98.45	5.49	103.1	Supplier-supplied	1	MARGINAL

Other recent GGPeps records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042737	Selank	GGPE-2603-J9708	Janoshik	2026-Q3	98.40	9.14	97.4	Buyer-sourced	0	FAIL
AX-2026-042804	Selank	GGPE-2602-G2056	Janoshik	2026-Q3	98.50	7.97	—	Supplier-supplied	0	FAIL
AX-2026-042803	Selank	GGPE-2602-G2056	Janoshik	2026-Q3	98.48	8.01	—	Laboratory-retained	1	FAIL
AX-2026-042802	Selank	GGPE-2602-G2056	Janoshik	2026-Q3	98.74	7.09	96.0	Supplier-supplied	0	FAIL
AX-2026-042796	Selank	GGPE-2602-G2056	Janoshik	2026-Q3	98.26	7.56	97.5	Buyer-sourced	0	FAIL
AX-2026-042648	Melanotan II	GGPE-2603-P8735	Janoshik	2026-Q3	99.10	6.97	—	Supplier-supplied	4	MARGINAL
AX-2026-042797	Selank	GGPE-2602-G2056	Medutest	2026-Q3	98.46	7.92	—	Buyer-sourced	0	FAIL
AX-2026-042669	CJC-1295 (no DAC)	GGPE-2606-E8495	Medutest	2026-Q3	98.61	4.06	95.5	Supplier-supplied	0	PASS